PREGABALIN AS AN OBJECT OF CHEMICAL-TOXICOLOGICAL ANALYSIS (LITERATURE REVIEW )
DOI:
https://doi.org/10.11603/mcch.2410-681X.2025.i1.15432Keywords:
pregabalin; epilepsy; chemical-toxicological analysis; poisoning; toxicological effectAbstract
Introduction. According to literature, the greatest toxicological danger is posed by drugs that affect the central nervous system. Epilepsy is one of the most common neurological diseases; according to WHO, about 50 million people in the world have this disorder. One of the new class of drugs used to treat pharmacoresistant forms of epilepsy, effective in neuropathic pain, generalized anxiety disorder and fibromyalgia is pregabalin. It is a structural analogue of gabapentin and is widely and effectively used in medical practice both abroad and in Ukraine.The purpose of studying pregabalin in the chemical-toxicological aspect is to analyze its pharmacological and toxicological characteristics, study the mechanisms of addiction formation, assess the risks of abuse, and develop methods for qualitative and quantitative determination of the drug in biological objects. This includes improving approaches to laboratory diagnostics of acute poisoning, identifying cases of abuse and assessing toxicological risks in combination with other psychoactive substances.The Aim of the Study is to summarize information on existing methods for the detection and quantitative determination of pregabalin in various objects.Conclusions. The analysis of literary sources showed that the development and validation of new and improvement of existing analytical and bioanalytical methods, the development of isolation methods from various objects are currently relevant for conducting chemical-toxicological analysis and pharmaceutical control.
References
Becerra-Bolacos Б. Pain Prevalence and Satisfaction with Pain Management in Inpatients: A Cross-Sectional Study / Б. Becerra-Bolacos, A. Armas-Domнnguez, L. Valencia et al. Healthcare (Basel). 2023. Vol. 11. No. 24. P. 311–316. DOI: 10.3390/ healthcare11243191.
International Association for the Study of Pain (IASP). Terminology IASP: Website. URL: http://www. iasp-pain.org/terminology. navItemNumber=576.
Дельва М. Ю. Теорія і практика застосування прегабаліну: погляд невролога, психіатра та клінічного фармаколога. / М. Ю. Дельва, Є. А. Хаустова, А. В. Зайченко. Неврологія і нейрохірургія. Східна Європа. 2020. Т. 10, № 4. С. 69–74. DOI: 10.1126/ science.288.5472.1769.
National Center for Biotechnology Information. PubChem Compound Summary for CID 5486971, Pregabalin PubChem. URL: https://pubchem. ncbi.nlm.nih.gov/compound/5486971.
Компендіум 2019 лікарські препарати / за ред. В.М. Коваленка. Київ : МОРІОН, 2019. 2480 с.
Tjandrawinata R. Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin / R. Tjandrawinata, E. Setiawati, R. Putri. Clinical Pharmacology: Advances and Applications. 2015. Vol. 7. P. 69–75. DOI: 10.2147/CPAA.S82143.
Henderson J. Blood-brain barrier: An impediment to neuropharmaceuticals / J. Henderson, M. Piquette-Miller. Clinical Pharmacology & Therapeutics. 2015. Vol. 97, No. 4. P. 308–313. DOI: 10.1016/j.neuroimage.2009.05.059.
Belliotti T.R. Structure–activity relationships of pregabalin and analogues that target the α₂-δ protein / T. R. Belliotti, T. О. Capiris, I. V. Ekhato J. Med. Chem. 2015. Vol. 48. P. 2294–2307. DOI: 10.1021/jm049762.
Silverman R.B. Basic science to blockbuster drug: invention of pregabalin (Lyrica®). Technology & Innovation. 2016. Vol. 17, No. 4. P. 153–158. DOI: 10.372 7/194982416X14520374942861.
Morrison E. A. Gabapentin and pregabalin: do the benefits outweigh the harms / E. A. Morrison, D. J. Sandilands, D. Webb. Journal of the Royal College of Physicians of Edinburgh. 2017. Vol. 47, No. 4. P. 310–313. DOI: 10.4997/jrcpe.2017.402.
Zhang Z., et al. Pregabalin mitigates microglial activation and neuronal injury by inhibiting HMGB1 signaling pathway in radiation-induced brain injury. Journal of Neuroinflammation. 2022. Vol. 19, No. 1. P. 61–65. DOI: 10.1186/s12974-022-02596-7.
Manjushree N. A review of the drug pregabalin / N. Manjushree, A. Chakraborty, K. Shashidhar, S. Narayanaswamy. International Journal of Basic & Clinical Pharmacology. 2017. Vol. 4, No. 4. P. 601–605. DOI: 10.18203/2319-2003.ijbcp20150359.
Quintero-Castellanos M. Pregabalin-induced liver injury – Case report. Colombian Journal of Anesthesiology. 2017. Vol. 45, No. 4. P. 349–352.
Buoli M. Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder / M. Buoli, A. Caldiroli, M. Serati. Expert Opinion on Drug Metabolism & Toxicology. 2017. Vol. 13, No. 3. P. 351–359. DOI: 10.1080/17425255.2017.1281247.
Rietjens S. J. Pregabalin poisoning: Evaluation of dose-toxicity relationship / S. J. Rietjens, M. A. Sikma, C. C. Hunault. British Journal of Clinical Pharmacology. 2022. Vol. 88, No. 3. P. 1288–1297.
Almuntashiri N. Determining the Toxicological Significance of Pregabalin in Fatalities / N. Almuntashiri, A. AL Farga. Biomedical Journal of Scientific & Technical Research. 2020. Vol. 30, No. 3. P. 284–290. DOI: 10.26717/BJSTR.2020.30.004962.
Sastre C. Pregabalin misuse: About seven cases of death in the region of Marseille / C. Sastre, V. Baillif- Couniou, N. Fabresse. Journal of Analytical and Clinical Toxicology. 2021. Vol. 30, No. 3. P. 234–239. DOI: 10.1016/toxac.2021.12.006.
Ashwini S. О. Pregabalin dependence with pregabalin induced intentional self-harm behavior. A case report / S. О. Ashwini, R. A. Dharmadhikari, S. I. Netto, V. A. Pawar. Indian Journal of Psychiatry. 2015. Vol. 57, No. 1. P. 110–116. DOI: 10.4103/0019-5545.148550.
Nahar L. K. Toxicological Relevance of Pregabalin in Heroin Users: A Two-Year Postmortem Population Study / L. K. Nahar, K. Murphy, S. Paterson. Journal of Analytical Toxicology. 2022. Vol. 46, No. 5. P. 471–478. DOI: 10.1093/jat/bkab070.
Shintani-Ishida K. Fatal pregabalin poisoning in Japan: A case report / K. Shintani-Ishida, M. Kawamoto, H. Kondo. Legal Medicine (Tokyo). 2024. Vol. 71. Р. 102–112. Doi: 10.1016/j.legalmed.2024.102522.
European Pharmacopoeia. 11 edn. 2022. URL: https://www.edqm.eu/en/european-pharmacopoeiaph.eur.11th-edition.
British Pharmacopoeia, 2021. URL: https://www. pharmacopoeia.com.
United States Pharmacopoeia. Validation of compendial procedures. USP40–NF35. 2017.
Japan Pharmacopoeia. 18th edition, June 7, 2021. URL: https://www.pmda.go.jp/english/rs-sb-std/ standards-development/jp/0029.html.
Walash M. I. Utility of certain nucleophilic aromatic substitution reactions for the assay of pregabalin in capsules / M. I. Walash, F. F. Belal, N. M. El-Enany. Chemistry Central Journal. 2016. Vol. 6, No. 4. P. 375–380. Doi: 10.1186/1752-153X-5-36.
Gujral R. S. Development and Validation of Pregabalin in Bulk, Pharmaceutical Formulations and in Human Urine Samples by UV Spectrophotometry / R. S. Gujral, S. M. Haque, P. Shanker. International Journal of Biomedical Science. 2019. Vol. 5, No. 2. P. 175–180. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3614770/.
Rashid M. Precise and Sensitive Ambient Temperature Based Analytical Colorimetric Method for Pregabalin / M. Rashid, T. Hussain, M. Sarfraz. Brazilian Journal of Pharmaceutical Sciences. 2022. Vol. 58. No. 2. P. 375–380. DOI: 10.1590/s2175-97902022e201048.
Swapna A. S. A New Validated UV-Visible Spectrophotometric Method for the Estimation of Pregabalin in its Pure and Dosage Form Using Bromophenol Blue / A. S. Swapna, K. Akshay, V. Anaswara. Asian Journal of Research in Chemistry. 2022. Vol. 15, No. 6. P. 417–421. DOI: 10.52711/0974-4150.2022.00073.
Naguib I. A. Ecologically Evaluated and FDA-Validated HPTLC Method for Assay of Pregabalin and Tramadol in Human Biological Fluids / I. A. Naguib, N. A. Ali, F. A. Elroby. Journal of Biomedical Chromatographia. 2021. Vol. 35, No. 4. P. 117–121. DOI: 10.1002/ bmc.5023.
Senthilkumar G. P. Spectrophotometric Determination of Pregabalin Through Schiff’s Base System Using Vanillin as Reagent in Bulk and Pharmaceutical Preparations / G. P. Senthilkumar, R. Sowmiya, M. Manoyogambiga. NeuroQuantology. 2022. Vol. 20, No. 15. P. 349–357. DOI: 10.14704/NQ.2022. 20.15.
Tafesse T. B. Gas Chromatography – Mass Spectrometry Determination of Pregabalin in Human Plasma Using Derivatization Method / T. B. Tafesse, F. Z. Mazdeh, A. Chalipour. Journal of Chromatographia. 2018. Vol. 81. P. 501–508. DOI: 10.1007/ s10337-017-3458-0.
Ianni F. GC-MS/MS Detects Potential Pregabalin Abuse in Susceptible Subjects’ Hair / F. Ianni, K. Aroni, A. Gili. Journal of Drug Testing and Analysis. 2018. Vol. 10, No. 6. P. 968–976. DOI: 10.1002/dta.2347.
Yoshikawa N. A Validated Fluorometric Method for the Rapid Determination of Pregabalin in Human Plasma Applied to Patients With Pain / N. Yoshikawa, T. Naito, T. Yagi. Therapeutic Drug Monitoring and Clinical Toxicology. 2016. Vol. 38, No. 5. P. 628–633. DOI: 10.1097/FTD.0000000000000325.
Hložek T. Gabapentin, Pregabalin and Vigabatrin Quantification in Human Serum by GC–MS After Hexyl Chloroformate Derivatization / T. Hložek, M. Bursovб, P. Coufal. Journal of Analytical Toxicology. 2016.Vol. 40, No. 9. P. 749–753. DOI: 10.1093/jat/bkw070.
Elessawy A. M. Determination of Pregabalin in Tissues and Fluids by Using GC / A. M. Elessawy, R. H. Abdel Elaziz, M. A. Shihata. Arch Clin Toxicol. 2019. Vol. 1, No. 1. P. 4–6.
Mudiam R. M. K. Development, validation and comparison of two microextraction techniques for the rapid and sensitive determination of pregabalin in urine and pharmaceutical formulations after ethyl chloroformate derivatization followed by gas chromatography – mass spectrometric analysis / R. M. K. Mudiam, A. Chauhan, R. Jain, R. Ch., G. Fatima, E. Malhotra, R.C. Murthy. J Pharm Biomed Anal. 2022. Vol. 70. P. 310–319. DOI: 10.1016/j.jpba.2012.05.001.
Ahmadkhaniha R. Validated HPLC Method for Quantification of Pregabalin in Human Plasma Using 1-Fluoro-2,4-dinitrobenzene as Derivatization Agent / R. Ahmadkhaniha, S. Mottaghi, M. Zargarpoor, E. Souri. J Pharm Biomed Anal. 2024. Vol. 50. P. 360–369. DOI: 10.1155/2014/450461.
Almalki A. H. ESI–LC–MS/MS for Therapeutic Drug Monitoring of Binary Mixture of Pregabalin and Tramadol: Human Plasma and Urine Applications / A. H. Almalki, N. A. Ali, F. A. Elroby, M. R. El Ghobashy, A. A. Emam, I. A. Naguib. Separations. 2021. Vol. 8. P. 21–27. DOI: https://doi.org/10.3390/separations8020021.
Mutalabisin F. Quantitation of Pregabalin by HPLC-UV Method using Ninhydrin Derivatization: Development and Validation / F. Mutalabisin, A. B. M. Helaluddin, P. Sengupta, F. Mohamed, B. Chatterjee. Current Pharmaceutical Analysis. 2021. Vol. 17, No. 1. P. 165–171. DOI: https://doi.org/10. 2174/1573412916666191114120213.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Medical and Clinical Chemistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
